8-K current report · filed Nov 16, 2026

Abbott Laboratories (ABT) 8-K Current Report: November 16, 2026

Item 5.02ABT overview

Short answer

Abbott Laboratories (ABT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Change-in-control agreements extended through December 31, 2028 for named executives other than CEO Robert B. Ford.

Abbott Laboratories 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Change-in-control agreements extended through December 31, 2028 for named executives other than CEO Robert B. Ford
  • Ford’s change-in-control agreement expires December 31, 2026
  • CEO exclusion creates potential transition or retention uncertainty around Abbott’s top executive role
  • No departure or succession announcement disclosed in this filing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Abbott Laboratories 8-K filings

Get the next ABT 8-K as it lands

Follow ABT for push alerts, or ask the research agent what this filing means.